Big pharma dominates ranking of stocks with best 5-year returns
By Laila Kearney
NEW YORK May 3 (Reuters) - U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns, according to an analysis released on Tuesday by Boston Consulting Group.
Drug company Regeneron Pharmaceuticals, which had an average annual total share return of 75.3 percent, was the top performer. Allergan and Gilead Sciences, with 43.3 percent and 41.4 percent average annual returns, respectively, took second and third place.
Companies with over $4 billion in market cap were considered for the list and ranked based on share gains and dividend yields between 2011 and 2015. Some 2,000 stocks were analyzed.
Big pharma had a total of four companies make the list. The fourth, Biogen, landed in the No. 6 spot.
Seven of the top 10 stocks ranked highest for creating value for shareholders were U.S. companies.
Several technology and media companies, including South Africa's Naspers, China's Tencent and U.S.-based Netflix, also made the list.
Besides pharma, industries that delivered the highest shareholder returns over the past five years include healthcare services, followed by media and publishing and travel and tourism. Commodity industries - oil, metals and mining - rank at the bottom of the list, BCG's report said.
Investors appear to be cashing in on some gains, with the S&P 500 Health Care Sector down 2.7 percent year-to-date. Continuación...